R D Petty

Summary

Affiliation: University of Aberdeen
Country: UK

Publications

  1. ncbi request reprint Bone metastasis from epithelial ovarian carcinoma
    Russell D Petty
    Department of Oncology, ANCHOR Unit, Aberdeen Royal Infirmary, UK
    Lancet Oncol 3:513. 2002
  2. ncbi request reprint A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity
    R D Petty
    Department of Oncology, ANCHOR Unit, Aberdeen Royal Infirmary, and University of Aberdeen, Institute of Medical Sciences, Foresterhill, UK
    Ann Oncol 14:1100-5. 2003
  3. ncbi request reprint Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy
    Russell D Petty
    Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK
    Curr Cancer Drug Targets 4:191-204. 2004
  4. ncbi request reprint Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application
    Russell D Petty
    Department of Oncology, Aberdeen and Oncology Research Group, Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, United Kingdom
    Clin Cancer Res 10:3237-48. 2004
  5. pmc APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling
    Russell D Petty
    University of Aberdeen, UK
    BMC Cancer 9:434. 2009
  6. ncbi request reprint Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer
    Russell D Petty
    Oncology Research Group, Department of Medicine and Therapeutics, Institute of Medical Sciences, School of Medicine, University of Aberdeen, Aberdeen, nited Kingdom
    J Clin Oncol 24:1729-44. 2006
  7. pmc Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study
    O M McNally
    Department of Gynaecology Oncology, Ward 43, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB15 2ZN, Scotland
    Br J Cancer 89:966-7. 2003
  8. doi request reprint Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation
    Nayef A Alymani
    Section of Translational Medical Sciences, Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom
    Eur J Cancer 46:869-79. 2010
  9. pmc Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers
    Gillian H Bain
    Medical and Experimental Oncology, Section of Translational Medical Sciences, Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Aberdeen, AB15 2ZD, Scotland
    Oncologist 15:270-84. 2010

Collaborators

Detail Information

Publications9

  1. ncbi request reprint Bone metastasis from epithelial ovarian carcinoma
    Russell D Petty
    Department of Oncology, ANCHOR Unit, Aberdeen Royal Infirmary, UK
    Lancet Oncol 3:513. 2002
  2. ncbi request reprint A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity
    R D Petty
    Department of Oncology, ANCHOR Unit, Aberdeen Royal Infirmary, and University of Aberdeen, Institute of Medical Sciences, Foresterhill, UK
    Ann Oncol 14:1100-5. 2003
    ..Here we have evaluated the efficacy and toxicity of mitomycin C, cisplatin and protracted infusional 5-fluorouracil (MCF)...
  3. ncbi request reprint Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy
    Russell D Petty
    Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, UK
    Curr Cancer Drug Targets 4:191-204. 2004
    ..This knowledge in combination with the advances already made (and ongoing) in pharmacokinetics may allow the full potential of fluoropyrimidines as anti-cancer agents to be realised in the future...
  4. ncbi request reprint Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application
    Russell D Petty
    Department of Oncology, Aberdeen and Oncology Research Group, Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, United Kingdom
    Clin Cancer Res 10:3237-48. 2004
    ..Taken together, these advances hold the promise of an improved understanding of the molecular biology of NSCLC and its treatment, which in turn will lead to improved outcomes for this deadly disease...
  5. pmc APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling
    Russell D Petty
    University of Aberdeen, UK
    BMC Cancer 9:434. 2009
    ..The aim was to identify novel 5FU resistance mechanisms and qualify these as candidate biomarkers and therapeutic targets...
  6. ncbi request reprint Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer
    Russell D Petty
    Oncology Research Group, Department of Medicine and Therapeutics, Institute of Medical Sciences, School of Medicine, University of Aberdeen, Aberdeen, nited Kingdom
    J Clin Oncol 24:1729-44. 2006
    ..Insight into clinical response to platinum-based chemotherapy (PBC) in non-small-cell lung cancer (NSCLC)...
  7. pmc Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study
    O M McNally
    Department of Gynaecology Oncology, Ward 43, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB15 2ZN, Scotland
    Br J Cancer 89:966-7. 2003
    ..We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only...
  8. doi request reprint Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation
    Nayef A Alymani
    Section of Translational Medical Sciences, Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom
    Eur J Cancer 46:869-79. 2010
    ..This holds considerable promise for facilitating the translation of predictive biomarkers from discovery to clinical implementation. Further enhancements could eventually be found through alignment with regulatory processes...
  9. pmc Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers
    Gillian H Bain
    Medical and Experimental Oncology, Section of Translational Medical Sciences, Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Aberdeen, AB15 2ZD, Scotland
    Oncologist 15:270-84. 2010
    ....